期刊
LUPUS
卷 13, 期 5, 页码 304-311出版社
SAGE PUBLICATIONS LTD
DOI: 10.1191/0961203303lu1017oa
关键词
biomarkers; clinical trials; multiplexed assays; SLE; surrogate markers
类别
资金
- DIVISION OF HEART AND VASCULAR DISEASES [N01HV028183] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR049328] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U19DK061934] Funding Source: NIH RePORTER
- NHLBI NIH HHS [N01-HV-28183] Funding Source: Medline
- NIAID NIH HHS [AI50854, AI50865] Funding Source: Medline
- NIAMS NIH HHS [AR49328] Funding Source: Medline
- NIDDK NIH HHS [DK61934] Funding Source: Medline
Validated biomarkers and surrogate markers are badly needed for monitoring patients with systemic lupus erythematosus (SLE), both for routine clinical care and for clinical trials research. SLE is difficult to study in clinical trials, in part because the disease is so heterogeneous. Very few useful markers have been identified, and even those that historically have been thought to be valid have been recently questioned. This report will focus on the use of emerging multiplexed assay formats that enable analysis of hundreds or even thousands of analytes simultaneously. Their potential and pitfalls for monitoring patients with SLE, particularly those enrolled in clinical trials testing novel therapeutics, will be discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据